



FOR IMMEDIATE RELEASE

Contacts

Daniel Lubin or Irene French

Radius Ventures

(212) 897-7778

[dlubin@radiusventures.com](mailto:dlubin@radiusventures.com) or [ifrench@radiusventures.com](mailto:ifrench@radiusventures.com)

**Radius Ventures Adds Dr. Dilip Mehta, M.D., Ph.D. as Venture Partner**

*Former SVP of Pfizer U.S. Clinical Research Expands Radius' Life Sciences Expertise*

**NEW YORK, NY – August 12, 2004** – Radius Ventures ([www.RadiusVentures.com](http://www.RadiusVentures.com)), a New York-based venture capital firm focused on health and life sciences investments, today announced the addition of Dr. Dilip Mehta, the former Senior Vice President, U.S. Clinical Research at Pfizer Central Research (NYSE: PFE), as a Venture Partner. Dr. Mehta will be teaming up with former Pfizer colleague, George Milne, Ph.D., who joined Radius last year as a Venture Partner. Dr. Milne is the former President of Pfizer Central Research (1993-2000) where he held global responsibility for Pfizer's human and animal health research and development.

Dr. Mehta, a clinical research physician, headed U.S. Clinical Research for Pfizer, including the design and implementation of Phase I through Phase III clinical trial protocols, and submissions of New Drug Applications ("NDA"s). During his tenure at Pfizer, Dr. Mehta was responsible for NDA submissions for many of Pfizer's current top-selling drugs, including Norvasc, Viagra, Zoloft, Zithromax, Diflucan and Cardura. Dr. Mehta managed a staff of over 450 scientists with an annual budget in excess of \$350 million, and established clinical research teams in Canada, China, India and Latin America. Prior to joining Pfizer Central Research in 1982, he worked at Hoechst AG (now Aventis) in Germany, India and in the United States, where he rose to Group Director, US Clinical Research. Dr. Mehta currently serves on the Psychopharmacology Advisory Committee of the FDA, is a member of the board of directors of Spectrum Pharmaceuticals, Inc., Esvee Pharmaceuticals Pvt Ltd. (India), Bharat Serums & Vaccines Limited (India), and is a member of the Scientific Board of Myomatrix Molecular Technologies LLC. Dr. Mehta received his M.B.B.S., M.D. and Ph.D. from the University of Bombay.

"I am delighted to be joining Radius Ventures. Radius has shaped a winning strategy for investing in the life science sector, and I am excited by the opportunity to bring my experience in pharmaceutical clinical research to the organization," said Dr. Dilip Mehta. "I am also looking forward to teaming up again with my friend and former colleague, George Milne, who I

worked with for over 15 years during my career at Pfizer. Together, as part of the Radius team, I believe we can make a difference in guiding Radius' portfolio companies through the complex and challenging aspects of pre-clinical and clinical development of promising compounds.”

“Adding an R&D executive of Dr. Mehta's caliber will further distinguish Radius as a value-added partner to companies, venture syndicates, and pharmaceutical industry partners who increasingly depend upon product in-licensing from small, innovative life sciences companies to meet their growth targets,” said Dr. George Milne, a Radius Venture Partner. “It is an exciting time at Radius, and Dilip's involvement adds to the energy, focus and depth of the organization.”

“This is an ideal time for life sciences venture investing – but success depends upon building an expert team that can vet critical investment issues, and support portfolio companies in all aspects of their operational and strategic development,” said Daniel Lubin, co-founder and Managing Partner of Radius Ventures. “Dilip's exceptional experience in clinical R&D strengthens Radius' ability to execute our investment strategy, particularly with regard to guiding our portfolio companies into human clinical trials, where enormous value can be created if companies take the right steps and implement well-designed protocols.”

### **About Radius Venture Partners**

Radius Ventures is a New York City-based venture capital firm focused on early-stage opportunities within the health and life sciences industry. Founded in 1997, Radius manages two funds with total committed capital of approximately \$100 million. The firm invests up to \$5 million in each of its portfolio companies and pursues a highly active investment style, providing substantial resources and direction to company management. Radius seeks opportunities across a broad spectrum including biotechnology and pharmaceuticals, medical devices and products, health and life sciences enterprise and application software, and healthcare services. On a selective basis, Radius considers later-stage health and life sciences investments where the firm can uniquely apply its industry and capital markets experience. Radius is licensed as a Small Business Investment Company (SBIC). For more information, visit: [www.RadiusVentures.com](http://www.RadiusVentures.com).

# # #